Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Lung Cancer: Page 2
Guardant Health highlights clinical results at IASLC
A study that used Guardant's GuardantInform database analyzed information from more than 2,000 patients with any EGFR mutation who had undergone osimertinib therapy, as well as outcomes from this therapy up to five years after it began. It showed a 12.5% incidence of the mutation in lung cancer patients unlikely to respond to the treatment, the company said.
August 7, 2022
Foundation Medicine highlights lung cancer study results
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
August 7, 2022
Biodesix touts VeriStrat test results
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
July 19, 2022
Veracyte genomic test classifies lung cancer risk in study
In a study published in the journal PLOS One, a group of researchers has clinically confirmed that Veracyte's Percepta Genomic Sequencing Classifier (GSC) can accurately classify lung cancer risk from inconclusive samples taken in a bronchoscopy.
July 19, 2022
Medial EarlySign, Roche partner on lung cancer detection
The goal is to deliver validated clinical machine learning models for lung cancer detection with EarlySign's LungFlag technology. The technology uses a variety of signals, including basic demographic, medical, drug, and routine clinical lab data.
July 7, 2022
Philips adopting proteomics results for patient management
The integration of proteomics results from the blood-based test -- along with the radiologic and patient history data currently used to determine treatment decisions -- can help create diagnostic efficiency for cancer care centers, Philips said.
June 29, 2022
Foundation Medicine gets FDA nod for NSCLC CDx
Rozlytrek is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) developed by Roche's Genentech.
June 8, 2022
Biodesix obtains Medicare coverage for lung nodule test
According to Biodesix, Nodify CDT measures seven autoantibodies associated with tumor antigens to help providers detect lung cancer across all histologies and stages.
June 6, 2022
Foundation Medicine, lung cancer groups partner in screening trial
The trial, named the "LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer" (LEADER), is the fourth study conducted through LCMC and a collaborative effort involving multiple academic study sites and pharmaceutical firms.
June 2, 2022
Lucence promotes lung cancer research at ASCO 2022
In three separate poster presentations, Lucence will share data showing how a total nucleic acid approach combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in one liquid biopsy test could increase actionable molecular information in lung cancer patients, according to the company.
May 31, 2022
CorePath and Cizzle partner to develop lung cancer test
The companies said they will first focus on offering the proprietary test in the U.S., where lung cancer accounts for 25% of all cancer deaths.
May 25, 2022
Biomarker data improves CT lung cancer screening's bottom line
The findings suggest a way to make CT lung cancer screening not only more useful but also economical when it comes to patient outcomes, wrote a team led by Zixuan Zhao, PhD, of Zhejiang University in Hangzhou, China.
May 23, 2022
Previous Page
Page 2 of 7
Next Page